Reaction
Hepatic Infection reporting signals
As of the last recalculation, Hepatic Infection appears in 1,254 FAERS reports alongside 28 co-occurring drug terms. The strongest observed disproportionality signal is NILOTINIB (PRR 31.7).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Nilotinib | 54 | 31.7 | 31.8 |
| Durvalumab | 26 | 21.6 | 21.7 |
| Granisetron Hydrochloride | 12 | 19.2 | 19.3 |
| Cimetidine | 10 | 17.4 | 17.4 |
| Valganciclovir Hydrochloride Powder, | 12 | 16.5 | 16.5 |
| Granisetron | 10 | 15.9 | 16.0 |
| Ursosiol | 17 | 14.7 | 14.7 |
| Valganciclovir | 16 | 14.3 | 14.3 |
| Valganciclovir Hydrochloride | 16 | 14.3 | 14.3 |
| Ursodiol | 18 | 13.9 | 13.9 |
| Rifaximin | 13 | 10.4 | 10.4 |
| Pancrelipase | 22 | 9.6 | 9.6 |
| Ivacaftor | 4 | 8.4 | 8.4 |
| Fam-Trastuzumab Deruxtecan-Nxki | 5 | 8.3 | 8.3 |
| Gemcitabine | 19 | 8.1 | 8.1 |
| Eltrombopag Olamine | 11 | 8.0 | 8.0 |
| Gemcitabine Hydrochloride | 24 | 7.6 | 7.6 |
| Sevelamer Carbonate | 5 | 7.2 | 7.3 |
| Deferasirox | 11 | 6.9 | 6.9 |
| Elexacaftor, Tezacaftor, And Ivacaftor | 5 | 6.7 | 6.7 |
| Atezolizumab | 15 | 6.5 | 6.5 |
| Lapatinib | 6 | 6.4 | 6.4 |
| Methoxy Polyethylene Glycol-Epoetin Beta | 4 | 6.0 | 6.0 |
| Vismodegib | 3 | 5.6 | 5.6 |
| Dornase Alfa | 4 | 3.4 | 3.4 |
| Orlistat | 5 | 3.2 | 3.2 |
| Osimertinib | 6 | 3.1 | 3.1 |
| Cinacalcet Hydrochloride | 6 | 2.1 | 2.1 |